London, 04 September 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Non-Small-Cell Lung Cancer Market 2014-2018, which is expected to grow at a slow pace at a CAGR of 3.62 percent during the forecast period of 2013-2018.
Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.
Use of personalized medicine is one of the potential trends in this market. It is based on the genetic structure of the patients, and has fewer adverse side effects than chemotherapy.
“The launch of new pipeline products is expected to change the present market scenario, with the entry of more biologics to treat the disease. These drugs are expected to show superior safety and efficacy results,” says Faisal Ghaus, Vice President of TechNavio.
Key Market Drivers
- High Unmet Need
- Rise in Disease Prevalence
- Promising Drug Pipeline
- Unhealthy Lifestyle
- Increase in Environmental Pollution
Key Market Trends
- Personalized Medicine
- Strategic Alliances
- Rise in Awareness
- Focus on Emerging Markets
Key Market Vendors
- AstraZeneca plc
- Celgene Corp.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
